Literature DB >> 8968761

Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees.

D J Day1, P W Speiser, E Schulze, M Bettendorf, J Fitness, F Barany, P C White.   

Abstract

Steroid 21-hydroxylase deficiency is among the most common inborn errors of metabolism in man. Characterization of mutations in the 21-hydroxylase gene (CYP21) has permitted genetic diagnosis, facilitated by the polymerase chain reaction (PCR). The most common mutation is conversion of an A or C at nt656 to a G in the second intron causing aberrant splicing of mRNA. Homozygosity for nt656G is associated with profoundly deficient adrenal cortisol and aldosterone synthesis, secondary hypersecretion of adrenal androgens, and a severe form of congenital adrenal hyperplasia (CAH) characterized by ambiguous genitalia and/or sodium wasting in newborns. During the course of genetic analysis of CYP21 mutations in CAH families, we and others have noticed a number of relatives genotyped as nt656G homozygotes, yet showing no clinical signs of disease. A number of lines of evidence have led us to propose that the putative asymptomatic nt656G/G individuals are incorrectly typed due to dropout of one haplotype during PCR amplification of CYP21. For prenatal diagnosis, we recommend that microsatellite typing be used as a supplement to CYP21 genotyping in order to resolve ambiguities at nt656.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968761     DOI: 10.1093/hmg/5.12.2039

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  24 in total

Review 1.  Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia.

Authors:  C G Brook
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

Review 2.  An overview of molecular diagnosis of steroid 21-hydroxylase deficiency.

Authors:  C E Keegan; A A Killeen
Journal:  J Mol Diagn       Date:  2001-05       Impact factor: 5.568

3.  Analysis of CYP21 coding polymorphisms in three ethnic populations: further evidence of nonamplifying CYP21 alleles among whites.

Authors:  I C Ozturk; W L Wei; L Palaniappan; M Rubenfire; A A Killeen
Journal:  Mol Diagn       Date:  2000-03

Review 4.  The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency.

Authors:  Hsien-Hsiung Lee
Journal:  J Hum Genet       Date:  2004-01-17       Impact factor: 3.172

5.  Novel nonsense mutation (W22X) in CYP21A2 gene causing salt-wasting congenital adrenal hyperplasia in a compound heterozygous girl.

Authors:  L Di Pasquale; S Indovina; M Wasniewska; S Mirabelli; P Porcelli; I Rulli; G Salzano; F De Luca
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

6.  Salt wasting phenotype in a compound heterozygous girl with P482S mutation associated with anovel mutation of CYP21 gene (Q481P).

Authors:  G Di Pasquale; M Wasniewska; M Caruso; G Salzano; M Coco; F Lombardo; F De Luca
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

7.  In Sicilian ethnic group non-classical congenital adrenal hyperplasia is frequently associated with a very mild genotype.

Authors:  M Wasniewska; G Di Pasquale; I Rulli; G Salzano; M Caruso; S Indovina; L Di Pasquale; G Zirilli; F De Luca
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

8.  Uniparental disomy for chromosome 6 results in steroid 21-hydroxylase deficiency: evidence of different genetic mechanisms involved in the production of the disease.

Authors:  A U López-Gutiérrez; L Riba; M L Ordoñez-Sánchez; S Ramírez-Jiménez; M Cerrillo-Hinojosa; M T Tusié-Luna
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

Review 9.  Congenital adrenal hyperplasia in pregnancy: approach depends on who is the 'patient'.

Authors:  Erin Keely; Janine Malcolm
Journal:  Obstet Med       Date:  2012-09-24

Review 10.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  Perrin C White
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.